Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CDRH director transition

This article was originally published in The Gray Sheet

Executive Summary

Center for Devices and Radiological Health Director Bruce Burlington holds "get acquainted" meetings with industry reps during the week of Feb. 22, his first week as CDRH chief. Among the visitors received by Burlington were Alan Magazine, president of the Health Industry Manufacturers Association; Robert Britain, director of the National Electrical Manufacturers Association's diagnostic imaging and therapy systems division; and Larry Pilot, an attorney with the Washington, D.C. law firm of McKenna & Cuneo who represents the Medical Device Manufacturers Association. Burlington also conferred with FDA Commissioner David Kessler and attorney Paul Rogers of Washington, D.C. firm Hogan & Hartson. When serving as a Democratic House member from Florida, Rogers drafted the 1976 medical device law....

Latest Headlines
See All
UsernamePublicRestriction

Register

MT000249

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel